Key result
This review summarizes the mechanisms of renal inflammation caused by acute hypernatremia and discusses the potential benefits of atrial natriuretic peptide, losartan, and tempol in attenuating injury.
This review highlights the molecular mechanisms of hypernatremia-induced renal inflammation and the potential therapeutic roles of ANP, losartan, and tempol.
No immediate practice change for hypernatremia; hypothesis-generating for trials of ANP, losartan, or tempol.
The body regulates plasma sodium levels within a small physiologic range, despite large variations in daily sodium and water intake. It is known that sodium transport in the kidneys plays an important role in hypoxia, being the major determinant of renal oxygen consumption. Tubular epithelial cell hypoxia is an important contributor to the development of renal inflammation, and the damage may progress to structural injury, ending in acute renal failure. In this review, we will summarize the renal inflammatory effects of high acute plasma sodium (acute hypernatremia), and the molecular mechanisms involved. We will also discuss recent findings related to the role of oxidative stress and angiotensin II (Ang II) in the pathogenesis of renal injury. We will comment on the effects of agents used to prevent or attenuate the inflammatory response, such as the atrial natriuretic peptide, the superoxide dismutase mimetic - tempol, and losartan.
No takes yet. Share an insight, caveat, or question.
Penna et al. (2015) conducted a review in Acute hypernatremia and renal inflammation. Atrial natriuretic peptide, losartan, and tempol was evaluated. This review summarizes the mechanisms of renal inflammation caused by acute hypernatremia and discusses the potential benefits of atrial natriuretic peptide, losartan, and tempol in attenuating injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: